Cadila shutters Indian ingredients plant after 26 workers test positive for COVID-19: report

CoronaVirus
Cadila's decision to close its Dholka plant comes weeks after a hub in Baddi was temporarily closed. (Pixabay)

Global drugmakers are working overtime to keep supplies coming amid the novel coronavirus pandemic. But in manufacturing facilities packed with workers, COVID-19 presents a particularly difficult challenge—and now one Indian plant has been forced to shutter due to a rash of infections. 

Cadila Pharmaceuticals has shut down an active pharmaceutical ingredients (API) plant in Dholka, Ahmedabad, India, after 26 employees tested positive for COVID-19, Reuters reported

Cadila ordered the facility closed Thursday and required 95 of its employees be quarantined at home. The drugmaker had also begun sanitizing the site, Reuters said. 

The shutdown at the Cadila plant comes just weeks after another Indian manufacturing hub was temporarily locked down as a COVID-19 hotspot and underscores the dangers the novel coronavirus has posed for the global supply chain. 

RELATED: India pharma manufacturing hub back up and running after COVID-19 lockdown: report

To help keep the facilities running at full capacity, the Indian government allowed a one-time movement of employees from Chandigarh state to Baddi to help staff the plants, according to Business Standard, as well as a resumption of intradistrict movement within Himachal Pradesh, where Baddi resides.

RELATED: Sanofi CEO: Amid COVID-19 supply push, one fever means 'maybe a half dozen' workers off the job

Suggested Articles

Bayer has withdrawn part of a proposed Roundup settlement after a judge questioned how it's handling potential future claims.

Consensus pegs cabotegravir peak sales at £750 million ($945 million), indicating it can grab about one-third of the current PrEP market.

The CEOs for COVID-19 vaccine partners Pfizer and BioNTech are sounding confident in their program as they gear up for phase 3.